Clearside Biomedical, Inc

(NASDAQ:CLSD)

Latest On Clearside Biomedical, Inc (CLSD):

Date/Time Type Description Signal Details
2023-05-11 18:03 ESTNewsClearside Biomedical GAAP EPS of -$0.15 misses by $0.01, revenue of $0.04M misses by $0.1MN/A
2023-05-11 18:03 ESTNewsClearside Biomedical, Inc. (CLSD) Q1 2023 Earnings Call TranscriptN/A
2023-03-10 06:19 ESTNewsClearside Biomedical GAAP EPS of -$0.16 misses by $0.04, revenue of $0.3M beats by $0.2MN/A
2023-03-10 06:19 ESTNewsClearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call TranscriptN/A
2023-02-02 16:37 ESTNewsClearside gains 12% as eye disease therapy cuts need for additional treatmentN/A
2022-11-09 22:06 ESTNewsClearside stock rises as CLS-AX shows promise in early-stage study in eye disorderN/A
2022-11-09 22:06 ESTNewsClearside Biomedical GAAP EPS of -$0.13 beats by $0.01, revenue of $0.26M misses by $6.26MN/A
2022-11-09 22:05 ESTNewsClearside Biomedical upgraded at Stifel on next-generation wet-AMD candidateN/A
2022-11-09 22:05 ESTNewsClearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call TranscriptN/A
2022-08-16 05:50 ESTNewsClearside Biomedical, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 21:16 ESTNewsClearside Biomedical GAAP EPS of -$0.13 beats by $0.01, revenue of $0.38M beats by $0.08MN/A
2022-08-09 21:15 ESTNewsClearside Biomedical Inc (CLSD) CEO George Lasezkay on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-09 00:10 ESTNewsClearside Biomedical Q2 2022 Earnings PreviewN/A
2022-05-12 15:06 ESTNewsClearside Biomedical, Inc.'s (CLSD) CEO George Lasezkay on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-11 21:08 ESTNewsClearside Biomedical GAAP EPS of -$0.13 misses by $0.10, revenue of $0.35M misses by $5.85MN/A
2022-05-11 01:44 ESTNewsClearside Biomedical Q1 2022 Earnings PreviewN/A
2022-04-13 15:37 ESTNewsClearside Biomedical: A Pivotal 2022 AheadN/A
2022-03-28 17:53 ESTNewsBausch Health, Clearside launch vision disorder therapy Xipere in USN/A
2022-03-11 08:57 ESTNewsClearside Biomedical GAAP EPS of $0.31 beats by $0.16, revenue of $25.7M beats by $8.26MN/A
2022-03-11 08:57 ESTNewsClearside Biomedical gains as milestones payments drive strong Q4 beatN/A
2022-03-11 08:57 ESTNewsClearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-09 21:30 ESTNewsClearside Biomedical Q4 2021 Earnings PreviewN/A
2021-12-22 14:22 ESTNewsClearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative PlayN/A
2021-12-21 18:27 ESTNewsWarning: CLSD is at high risk of performing badlyN/A
2021-12-14 11:57 ESTNewsClearside Biomedical to join Nasdaq Biotechnology IndexN/A
2021-11-12 18:40 ESTNewsRegenxbio posts additional mid-stage data for RGX-314 in wet AMDN/A
2021-11-11 03:27 ESTNewsClearside Biomedical EPS misses by $0.01, beats on revenueN/A
2021-11-11 03:27 ESTNewsClearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-25 15:07 ESTNewsBausch Health, Clearside Biomedical win FDA approval for XIPERE in eye diseaseN/A
2021-09-21 14:34 ESTNewsClearside Biomedical (CLSD) Investor Presentation - SlideshowN/A
2021-09-21 14:20 ESTNewsClearside Biomedical completes dosing in cohort 2 of early-stage CLS-AX wet AMD trialN/A
2021-09-09 22:23 ESTNewsClearside Biomedical expands XIPERE license agreement with Arctic VisionN/A
2021-08-11 18:14 ESTNewsClearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 22:22 ESTNewsClearside Biomedical EPS beats by $0.01, beats on revenueN/A
2021-08-07 16:00 ESTNewsClearside's Value Proposition Is Far From ClearN/A
2021-07-21 00:53 ESTNewsFDA accepts Bausch Health and Clearside's XIPERE NDA for reviewN/A
2021-07-21 00:40 ESTNewsClearside Biomedical climbs after positive results from early-stage wet AMD trialN/A
2021-07-21 00:39 ESTNewsCATB, XELB, CLSD and DTEA among after-hours moversN/A
2021-07-21 00:39 ESTNewsSage cut to neutral at Citi on data from depression trial, Bionano is a new buy at BTIG; in today’s analyst actionN/A
2021-07-21 00:38 ESTNewsOpthea surges 41% as potential beneficiary of Clearside wet AMD dataN/A
2021-05-03 19:53 ESTNewsClearside Biomedical resubmits eye treatment XIPERE NDAN/A
2021-03-13 03:21 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 04:39 ESTNewsClearside Biomedical EPS misses by $0.03, misses on revenueN/A
2021-03-11 04:38 ESTNewsClearside Biomedical, Inc. (CLSD) CEO George Lasezkay on Q4 2020 Results - Earnings Call TranscriptN/A
2021-03-11 03:23 ESTEarnings EstimateAn EPS average of -$0.42 is estimated for the 2022 year.Sell
2021-03-11 03:23 ESTEarnings EstimateAn EPS average of -$0.11 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-02 09:56 ESTNewsClearside Biomedical completes dosing in early-stage wet AMD study cohort 1N/A
2021-02-23 03:24 ESTAnalyst RatingThe Analyst Target Price has increased from $6.13 to $6.38.Buy
2021-02-22 18:39 ESTNewsCircling Back On Clearside BiomedicalN/A
2021-02-10 07:21 ESTAnalyst RatingThe Analyst Target Price has increased from $5.9 to $6.13.Buy

About Clearside Biomedical, Inc (CLSD):

Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.

CLSD Quotes by TradingView

See Advanced Chart

General

  • Name Clearside Biomedical, Inc
  • Symbol CLSD
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Fiscal Year EndDecember
  • IPO Date2016-06-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.clearsidebio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 16.44
  • Price/Book (Most Recent Quarter) 18.28
  • Enterprise Value Revenue 18.36
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.30
  • Next Year EPS Estimate -$0.41
  • Next Quarter EPS Estimate -$0.08
  • Profit Margin -231%
  • Operating Margin -227%
  • Return on Assets -49%
  • Return on Equity -183%
  • Revenue 7.89 million
  • Earnings Per Share -$1.96
  • Revenue Per Share $0.17
  • Gross Profit 7.89 million
  • Quarterly Earnings Growth -99.4%
View More

Highlights

  • Market Capitalization 161.93 million
  • EBITDA -68909000
  • PE Ratio -2.26
  • Analyst Target Price $6.38
  • Book Value Per Share $0.17
View More

Share Statistics

  • Shares Outstanding 57.42 million
  • Shares Float 41.76 million
  • % Held by Insiders 830%
  • % Held by Institutions 41.37%
  • Shares Short 428692
  • Shares Short Prior Month 515638
  • Short Ratio 0.75
  • Short % of Float 1%
  • Short % of Shares Outstanding 1%
View More

Technicals

  • Beta 1.42
  • 52 Week High $4.53
  • 52 Week Low $1.25
  • 50 Day Moving Average 3.42
  • 200 Day Moving Average 2.38
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Clearside Biomedical, Inc (CLSD) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Clearside Biomedical, Inc (CLSD) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.14-$0.11-27.27%
2020-09-302020-11-10$N/A-$0.05-$0.1257.16%
2020-06-302020-08-10$N/A-$0.13-$0.07-77.35%
2020-03-312020-05-08$4.1 million-$0.07-$0.03-133.33%
2019-12-312020-03-11$1.94 million-$0.07-$0.1030%
2019-09-302019-11-06$141000-$0.17-$0.16-7.94%
2019-06-302019-08-07$45000-$0.22-$0.3943.59%
2019-03-312019-05-08$45000-$0.45-$0.40-11.66%
2018-12-312019-03-12$30000-$0.68-$0.57-20.08%
2018-09-302018-11-08$N/A-$0.75-$0.63-18.67%
2018-06-302018-08-08$N/A-$0.65-$0.58-12.83%
2018-03-312018-05-09$N/A-$0.62-$0.58-6.47%
2017-12-312018-03-14$55000-$0.65-$0.707.39%
2017-09-302017-11-08$155000-$0.72-$0.55-30.46%
2017-06-302017-08-09$130000-$0.54-$0.41-30.94%
2017-03-312017-05-10$5000-$0.41-$0.435.55%
2016-12-312017-03-14$5000-$0.45-$0.33-38.46%
2016-09-302016-11-09$5000-$0.28-$0.3825.67%
2016-06-302016-08-11$5000-$0.62-$0.45-38.8%
2016-03-312016-06-27$505000-$0.45$0.00

Clearside Biomedical, Inc (CLSD) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A 3.81 million 1.31 million
Income Before Tax N/A N/A N/A -2.91 million -3.1 million
Selling General Administrative N/A N/A N/A 3.12 million 3.65 million
Gross Profit N/A N/A N/A N/A 1.94 million
Ebit N/A N/A N/A -2.79 million -3.01 million
Operating Income N/A N/A N/A -2.84 million -3.01 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A 4.1 million 1.94 million
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A -75000 -83000
Net Income From Continuing Operations N/A N/A N/A -2.91 million -3.1 million
Net Income Applicable to Common Shares -7.11 million -2.43 million -5.75 million -2.91 million -3.1 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities -1.1 million 208000 N/A N/A N/A
Total Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Net Borrowings N/A -4.35 million N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities -14000 1.23 million N/A N/A N/A
Change in Cash N/A N/A N/A N/A N/A
Total Cash from Operating Activities -2.66 million -3.22 million N/A N/A N/A
Depreciation N/A N/A N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 841000 940000 N/A N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A 14.6 million 15.62 million
Total Stockholder Equity N/A N/A N/A 10.44 million 11.16 million
Other Current Liabilities N/A 5 million N/A N/A N/A
Total Assets N/A N/A N/A 25.04 million 26.78 million
Common Stock 8.76 million 48000 46000 10.44 million 11.16 million
Other Current Assets N/A 9000 N/A 1.68 million N/A
Retained Earnings N/A -248.76 million -246.32 million -240.57 million N/A
Other Liabilities 9.57 million N/A N/A 9.42 million 10.47 million
Other Assets 2.04 million 360000 360000 3.75 million 4.18 million
Cash N/A N/A N/A 20.93 million 22.6 million
Total Current Liabilities N/A 8.21 million N/A 13.77 million N/A
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment N/A 1.02 million 1.1 million 1.18 million N/A
Total Current Assets 17.29 million 16.02 million N/A 23.51 million 22.6 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 8.76 million 8.12 million 7.29 million 10.44 million 11.16 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 5.15 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable N/A 909000 N/A 1.63 million N/A

Clearside Biomedical, Inc (CLSD) Chart:

Clearside Biomedical, Inc (CLSD) News:

Below you will find a list of latest news for Clearside Biomedical, Inc (CLSD) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Clearside Biomedical, Inc (CLSD) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-01-170.50CALL0 00TRUE00
2025-01-1710CALL0 00TRUE00
2025-01-171.50.5CALL50 121194.15FALSE00
2025-01-172.50.35CALL0 880207.21FALSE00
2025-01-1750.25CALL5 113241.65FALSE0.250
2025-01-177.50CALL0 00FALSE00
2025-01-170.50PUT0 00FALSE00
2025-01-1710PUT0 00FALSE00
2025-01-171.50.2PUT0 1030TRUE00
2025-01-172.51.3PUT0 50TRUE00
2025-01-1750PUT0 00TRUE00
2025-01-177.50PUT0 0206.05TRUE00
2025-04-170.50CALL0 00TRUE00
2025-04-1710.4CALL0 10TRUE00
2025-04-171.50.55CALL6 35156.49FALSE00
2025-04-172.50.4CALL0 1356184.31FALSE00
2025-04-1750.3CALL0 120FALSE00
2025-04-177.50.2CALL0 180FALSE00
2025-04-170.50PUT0 00FALSE00
2025-04-1710PUT0 00FALSE00
2025-04-171.50PUT0 00TRUE00
2025-04-172.50PUT0 00TRUE00
2025-04-1750PUT0 0207.59TRUE00
2025-04-177.50PUT0 0182.15TRUE00

Latest CLSD Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST70$1.34
Jun 13, 2022 7:59 PM EST18$1.34
Jun 13, 2022 7:59 PM EST10$1.34
Jun 13, 2022 7:59 PM EST10$1.34
Jun 13, 2022 7:59 PM EST5$1.33

Clearside Biomedical, Inc (CLSD) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120039115/0001209191-20-039115-index.htm
2020-01-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1539029/000000000020000364/0000000000-20-000364-index.htm
2020-05-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1539029/000000000020004294/0000000000-20-004294-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000021545719006800/0000215457-19-006800-index.htm
2019-05-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000021545719007853/0000215457-19-007853-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000090221919000019/0000902219-19-000019-index.htm
2019-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000090221919000026/0000902219-19-000026-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000092963819000263/0000929638-19-000263-index.htm
2019-01-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000093343019000001/0000933430-19-000001-index.htm
2019-11-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000093343019000008/0000933430-19-000008-index.htm
2019-11-26SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000093343019000009/0000933430-19-000009-index.htm
2020-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000093343020000006/0000933430-20-000006-index.htm
2020-08-134/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000093343020000007/0000933430-20-000007-index.htm
2018-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000119312518125827/0001193125-18-125827-index.htm
2018-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1539029/000119312518136675/0001193125-18-136675-index.htm
2018-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1539029/000119312518136688/0001193125-18-136688-index.htm
2019-04-26DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1539029/000119312519122376/0001193125-19-122376-index.htm
2019-04-26DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1539029/000119312519122388/0001193125-19-122388-index.htm
2019-05-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000119312519153358/0001193125-19-153358-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1539029/000119312519195750/0001193125-19-195750-index.htm
2019-12-04SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1539029/000119312519306233/0001193125-19-306233-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1539029/000119312520124364/0001193125-20-124364-index.htm
2020-04-29DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1539029/000119312520124372/0001193125-20-124372-index.htm
2020-05-08S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1539029/000119312520137674/0001193125-20-137674-index.htm
2020-05-19S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1539029/000119312520145277/0001193125-20-145277-index.htm
2020-05-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1539029/000119312520145280/0001193125-20-145280-index.htm
2020-05-20CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1539029/000119312520147430/0001193125-20-147430-index.htm
2020-05-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1539029/000119312520150268/0001193125-20-150268-index.htm
2018-05-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118030253/0001209191-18-030253-index.htm
2018-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118031802/0001209191-18-031802-index.htm
2018-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118035387/0001209191-18-035387-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118038979/0001209191-18-038979-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118038982/0001209191-18-038982-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118038983/0001209191-18-038983-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118038984/0001209191-18-038984-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118038986/0001209191-18-038986-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118038988/0001209191-18-038988-index.htm
2018-06-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118038990/0001209191-18-038990-index.htm
2018-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118039537/0001209191-18-039537-index.htm
2018-09-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118052554/0001209191-18-052554-index.htm
2018-09-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118052558/0001209191-18-052558-index.htm
2018-12-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919118061355/0001209191-18-061355-index.htm
2019-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119008162/0001209191-19-008162-index.htm
2019-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119008164/0001209191-19-008164-index.htm
2019-02-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119008168/0001209191-19-008168-index.htm
2019-03-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119019884/0001209191-19-019884-index.htm
2019-04-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119024303/0001209191-19-024303-index.htm
2019-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119034404/0001209191-19-034404-index.htm
2019-06-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119034413/0001209191-19-034413-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119038765/0001209191-19-038765-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119038767/0001209191-19-038767-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119038770/0001209191-19-038770-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119038772/0001209191-19-038772-index.htm
2019-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119038778/0001209191-19-038778-index.htm
2019-08-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119045172/0001209191-19-045172-index.htm
2019-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119050353/0001209191-19-050353-index.htm
2019-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119050356/0001209191-19-050356-index.htm
2019-11-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119055905/0001209191-19-055905-index.htm
2019-11-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119056254/0001209191-19-056254-index.htm
2019-11-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919119058129/0001209191-19-058129-index.htm
2020-01-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120003104/0001209191-20-003104-index.htm
2020-01-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120003105/0001209191-20-003105-index.htm
2020-03-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120018886/0001209191-20-018886-index.htm
2020-04-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120025447/0001209191-20-025447-index.htm
2020-04-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120025448/0001209191-20-025448-index.htm
2020-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120028794/0001209191-20-028794-index.htm
2020-05-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120031325/0001209191-20-031325-index.htm
2020-06-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120034062/0001209191-20-034062-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120037942/0001209191-20-037942-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120037947/0001209191-20-037947-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120037949/0001209191-20-037949-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120037950/0001209191-20-037950-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120037952/0001209191-20-037952-index.htm
2020-06-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120037955/0001209191-20-037955-index.htm
2020-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120039115/0001209191-20-039115-index.htm
2020-08-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120047348/0001209191-20-047348-index.htm
2020-09-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000120919120051898/0001209191-20-051898-index.htm
2019-09-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000149315219014412/0001493152-19-014412-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1539029/000149315220002371/0001493152-20-002371-index.htm
2018-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018012109/0001564590-18-012109-index.htm
2018-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1539029/000156459018012957/0001564590-18-012957-index.htm
2018-05-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1539029/000156459018012986/0001564590-18-012986-index.htm
2018-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018013662/0001564590-18-013662-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018015881/0001564590-18-015881-index.htm
2018-06-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018015948/0001564590-18-015948-index.htm
2018-07-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018016609/0001564590-18-016609-index.htm
2018-07-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018017423/0001564590-18-017423-index.htm
2018-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018020180/0001564590-18-020180-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1539029/000156459018020519/0001564590-18-020519-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018023605/0001564590-18-023605-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018028277/0001564590-18-028277-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1539029/000156459018028565/0001564590-18-028565-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018029136/0001564590-18-029136-index.htm
2018-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459018031115/0001564590-18-031115-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019000269/0001564590-19-000269-index.htm
2019-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019003375/0001564590-19-003375-index.htm
2019-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019007356/0001564590-19-007356-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019007456/0001564590-19-007456-index.htm
2019-03-1510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1539029/000156459019007887/0001564590-19-007887-index.htm
2019-03-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1539029/000156459019007893/0001564590-19-007893-index.htm
2019-04-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019011370/0001564590-19-011370-index.htm
2019-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019011832/0001564590-19-011832-index.htm
2019-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019016827/0001564590-19-016827-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1539029/000156459019018552/0001564590-19-018552-index.htm
2019-05-10S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1539029/000156459019018570/0001564590-19-018570-index.htm
2019-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019022968/0001564590-19-022968-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019030065/0001564590-19-030065-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1539029/000156459019030795/0001564590-19-030795-index.htm
2019-08-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019032776/0001564590-19-032776-index.htm
2019-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019033940/0001564590-19-033940-index.htm
2019-10-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019036495/0001564590-19-036495-index.htm
2019-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019037184/0001564590-19-037184-index.htm
2019-10-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019037476/0001564590-19-037476-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019041028/0001564590-19-041028-index.htm
2019-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1539029/000156459019042264/0001564590-19-042264-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019043930/0001564590-19-043930-index.htm
2019-11-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019044288/0001564590-19-044288-index.htm
2019-12-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459019046148/0001564590-19-046148-index.htm
2020-01-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020000224/0001564590-20-000224-index.htm
2020-01-10S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1539029/000156459020000761/0001564590-20-000761-index.htm
2020-01-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1539029/000156459020001172/0001564590-20-001172-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020010060/0001564590-20-010060-index.htm
2020-03-1310-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1539029/000156459020010810/0001564590-20-010810-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020010820/0001564590-20-010820-index.htm
2020-03-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1539029/000156459020010829/0001564590-20-010829-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020011163/0001564590-20-011163-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020015814/0001564590-20-015814-index.htm
2020-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020017812/0001564590-20-017812-index.htm
2020-04-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020018985/0001564590-20-018985-index.htm
2020-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020023233/0001564590-20-023233-index.htm
2020-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1539029/000156459020023620/0001564590-20-023620-index.htm
2020-05-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1539029/000156459020023650/0001564590-20-023650-index.htm
2020-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020029798/0001564590-20-029798-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1539029/000156459020038893/0001564590-20-038893-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1539029/000156459020038932/0001564590-20-038932-index.htm
2019-12-04DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1539029/000177539419000001/0001775394-19-000001-index.htm
2020-01-17EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1539029/999999999520000122/9999999995-20-000122-index.htm
2020-05-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1539029/999999999520001244/9999999995-20-001244-index.htm
2018-09-11CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1539029/999999999718007794/9999999997-18-007794-index.htm

Clearside Biomedical, Inc (CLSD) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Clearside Biomedical, Inc (CLSD). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 830%
Institutional Ownership: 4137%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-08-07GEORGE M LASEZKAYCEOBuy100,000.00100,000.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119045172/0001209191-19-045172-index.htm
2019-05-31Charles A. DeignanChief Financial OfficerBuy50,000.00126,356.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119034404/0001209191-19-034404-index.htm
2019-09-18Charles A. DeignanChief Financial OfficerBuy70,000.00196,356.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119050353/0001209191-19-050353-index.htm
2019-11-12Charles A. DeignanChief Financial OfficerBuy7,500.001.148,550.00203,856.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119056254/0001209191-19-056254-index.htm
2019-09-18GEORGE M LASEZKAYCEOBuy110,000.00210,000.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119050356/0001209191-19-050356-index.htm
2020-06-01Charles A. DeignanChief Financial OfficerSell14,992.001.8828,184.96220,827.00https://www.sec.gov/Archives/edgar/data/1539029/000120919120034062/0001209191-20-034062-index.htm
2019-11-11GEORGE M LASEZKAYCEOBuy12,000.001.1613,920.00222,000.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119055905/0001209191-19-055905-index.htm
2020-01-08Charles A. DeignanChief Financial OfficerBuy25,000.00228,856.00https://www.sec.gov/Archives/edgar/data/1539029/000120919120003105/0001209191-20-003105-index.htm
2020-01-08GEORGE M LASEZKAYCEOBuy66,250.00288,250.00https://www.sec.gov/Archives/edgar/data/1539029/000120919120003104/0001209191-20-003104-index.htm
2020-08-12BRADFORD T WHITMORE10% Share HolderBuy300,000.001.63489,120.002,900,000.00https://www.sec.gov/Archives/edgar/data/1539029/000093343020000006/0000933430-20-000006-index.htm
2020-08-13BRADFORD T WHITMORE10% Share HolderBuy50,000.001.6582,560.002,950,000.00https://www.sec.gov/Archives/edgar/data/1539029/000093343020000006/0000933430-20-000006-index.htm
2020-09-22GEORGE M LASEZKAYCEOSell13,411.001.5921,323.49302,689.00https://www.sec.gov/Archives/edgar/data/1539029/000120919120051898/0001209191-20-051898-index.htm
2020-05-12GEORGE M LASEZKAYCEOSell32,150.001.9963,978.50311,100.00https://www.sec.gov/Archives/edgar/data/1539029/000120919120028794/0001209191-20-028794-index.htm
2020-03-11GEORGE M LASEZKAYCEOBuy50,000.00343,250.00https://www.sec.gov/Archives/edgar/data/1539029/000120919120018886/0001209191-20-018886-index.htm
2018-05-18Clay ThorpDirectorSell61,139.0013.16804,589.243,466,394.00https://www.sec.gov/Archives/edgar/data/1539029/000120919118031802/0001209191-18-031802-index.htm
2018-05-17Clay ThorpDirectorSell100,000.0013.031,303,000.003,527,533.00https://www.sec.gov/Archives/edgar/data/1539029/000120919118031802/0001209191-18-031802-index.htm
2018-06-04Daniel H. WhitePresident and CEOBuy11,000.009.0799,770.00483,335.00https://www.sec.gov/Archives/edgar/data/1539029/000120919118035387/0001209191-18-035387-index.htm
2019-11-22Clay ThorpDirectorBuy1,518,026.001.051,599,999.404,984,420.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119058129/0001209191-19-058129-index.htm
2020-05-20Nancy J HutsonDirectorBuy5,000.001.859,250.005,000.00https://www.sec.gov/Archives/edgar/data/1539029/000120919120031325/0001209191-20-031325-index.htm
2019-05-31Brion S. RaymondChief Commercial OfficerBuy50,000.0050,000.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119034413/0001209191-19-034413-index.htm
2020-08-18William D. HumphriesDirectorBuy5,586.001.789,943.085,586.00https://www.sec.gov/Archives/edgar/data/1539029/000120919120047348/0001209191-20-047348-index.htm
2018-05-11Gerald D. CagleDirectorBuy45,454.000.4018,181.6068,895.00https://www.sec.gov/Archives/edgar/data/1539029/000120919118030253/0001209191-18-030253-index.htm
2019-03-15Charles A. DeignanChief Financial OfficerBuy10,000.001.3613,600.0076,356.00https://www.sec.gov/Archives/edgar/data/1539029/000120919119019884/0001209191-19-019884-index.htm
2018-06-25Gerald D. CagleDirectorBuy8,618.008.8175,924.5877,513.00https://www.sec.gov/Archives/edgar/data/1539029/000120919118039537/0001209191-18-039537-index.htm
2018-12-06Clay ThorpDirectorBuy8,000.001.3610,880.008,000.00https://www.sec.gov/Archives/edgar/data/1539029/000120919118061355/0001209191-18-061355-index.htm
2018-06-25Gerald D. CagleDirectorBuy2,632.009.1123,977.5280,145.00https://www.sec.gov/Archives/edgar/data/1539029/000120919118039537/0001209191-18-039537-index.htm